Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab-Reference-Cited by-同舟云学术

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Published:2011-09-07 Issue:99 Volume:3 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Yonesaka Kimio¹²³⁴,Zejnullahu Kreshnik¹²,Okamoto Isamu³,Satoh Taroh³,Cappuzzo Federico⁵,Souglakos John⁶⁷,Ercan Dalia¹²,Rogers Andrew¹²,Roncalli Massimo⁵,Takeda Masayuki³,Fujisaka Yasuhito³,Philips Juliet²,Shimizu Toshio³,Maenishi Osamu⁸,Cho Yonggon⁹,Sun Jason¹²,Destro Annarita⁴,Taira Koichi¹⁰,Takeda Koji¹⁰,Okabe Takafumi¹²,Swanson Jeffrey¹²,Itoh Hiroyuki⁸,Takada Minoru¹¹,Lifshits Eugene¹²,Okuno Kiyotaka¹³,Engelman Jeffrey A.¹²,Shivdasani Ramesh A.²¹⁴,Nishio Kazuto¹⁵,Fukuoka Masahiro⁴¹¹,Varella-Garcia Marileila⁹,Nakagawa Kazuhiko³,Jänne Pasi A.¹²¹⁴

Affiliation:

1. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

3. Department of Medical Oncology, Kinki University School of Medicine, Osaka 589-8511, Japan.

4. Department of Medical Oncology, Izumi Municipal Hospital, Osaka 594-0071, Japan.

5. Istituto Clinico Humanitas, Rozzano 20089, Italy.

6. Laboratory of Tumor Biology, Medical School, University of Crete, Heraklion 71110, Greece.

7. University Hospital of Heraklion, Heraklion 71110, Greece.

8. Department of Pathology, Kinki University School of Medicine, Osaka 589-8511, Japan.

9. University of Colorado Cancer Center, Aurora, CO 80045, USA.

10. Department of Clinical Oncology, Osaka City General Hospital, Osaka 534-0021, Japan.

11. Department of Medical Oncology, Kinki University School of Medicine, Sakai Hospital, Osaka 590-0132, Japan.

12. Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA.

13. Department of Surgery, Kinki University School of Medicine, Osaka 589-8511, Japan.

14. Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA.

15. Department of Genome Biology, Kinki University School of Medicine, Osaka 589-8511, Japan.

Abstract

Several cancers become resistant to cetuximab by activating a bypass signaling pathway and preventing cetuximab inhibition of ERK1/2-stimulated growth.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference38 articles.

1. Cetuximab for the Treatment of Colorectal Cancer

2. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

3. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

4. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

5. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Cited by 532 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer;Nature Communications;2024-02-01

2. Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer;Cancers;2024-01-18

3. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers;International Journal of Molecular Sciences;2024-01-15

4. Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer;npj Precision Oncology;2024-01-10

5. Colorectal cancer: Genetic alterations, novel biomarkers, current therapeutic strategies and clinical trials;Gene;2024-01